The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically…

AML, Adult

~Estimated

~$10 – $750

Abramson Cancer Center at Penn MedicineNCT05909501

Phase 1

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), p…

AML, AdultMDS

~Estimated

~$10 – $8,750

Stelexis BioSciencesNCT06533761

Phase 1

A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy …

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

~Estimated

~$10 – $7,500

Richard Stone, MDNCT06313437